Expression of high affinity folate receptor in breast cancer brain metastasis

Oncotarget

Volumn 6, Issue 30, 2015, Pages 30327-30333

  Leone, José Pablo ^a   Bhargava, Rohit ^b   Theisen, Brian K ^b   Hamilton, Ronald L ^b   Lee, Adrian V ^b   Brufsky, Adam M ^b  

^a UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Brain metastasis; Breast cancer; Folate receptor alpha; High affinity folate receptor; Metastatic breast cancer

Indexed keywords

FOLATE RECEPTOR; HIGH AFFINITY FOLATE RECEPTOR; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BRAIN METASTASIS; BREAST CANCER; BREAST CANCER BRAIN METASTASIS; CANCER PROGNOSIS; CLINICAL ARTICLE; HIGH RISK POPULATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; OVERALL SURVIVAL; PRIMARY TUMOR; PROTEIN EXPRESSION; TUMOR DIFFERENTIATION; BRAIN NEOPLASMS; BREAST NEOPLASMS; CELL DIFFERENTIATION; CHEMISTRY; FEMALE; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; PATHOLOGY; PREDICTIVE VALUE; PROGNOSIS; RETROSPECTIVE STUDY; RISK FACTOR; SECONDARY; TIME FACTOR; YOUNG ADULT;

ADULT; AGED; BRAIN NEOPLASMS; BREAST NEOPLASMS; CELL DIFFERENTIATION; FEMALE; FOLATE RECEPTORS, GPI-ANCHORED; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; YOUNG ADULT;

EID: 84945121514     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.4639     Document Type: Article

References (26)

1. Antony AC. The biological chemistry of folate receptors. Blood. 1992; 79:2807-2820.
2. Spinella MJ, Brigle KE, Sierra EE and Goldman ID. Distinguishing between folate receptor-alpha-mediated transport and reduced folate carrier-mediated transport in L1210 leukemia cells. The Journal of biological chemistry. 1995; 270:7842-7849.
3. Parker N, Turk MJ, Westrick E, Lewis JD, Low PS and Leamon CP. Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay. Analytical biochemistry. 2005; 338:284-293.
4. Weitman SD, Lark RH, Coney LR, Fort DW, Frasca V, Zurawski VR, Jr. and Kamen BA. Distribution of the folate receptor GP38 in normal and malignant cell lines and tissues. Cancer research. 1992; 52:3396-3401.
5. Toffoli G, Cernigoi C, Russo A, Gallo A, Bagnoli M and Boiocchi M. Overexpression of folate binding protein in ovarian cancers. International journal of cancer Journal international du cancer. 1997; 74:193-198.
6. Ross JF, Chaudhuri PK and Ratnam M. Differential regulation of folate receptor isoforms in normal and malignant tissues in vivo and in established cell lines. Physiologic and clinical implications. Cancer. 1994; 73:2432-2443.
7. Bottero F, Tomassetti A, Canevari S, Miotti S, Menard S and Colnaghi MI. Gene transfection and expression of the ovarian carcinoma marker folate binding protein on NIH/3T3 cells increases cell growth in vitro and in vivo. Cancer research. 1993; 53:5791-5796.
8. Toffoli G, Russo A, Gallo A, Cernigoi C, Miotti S, Sorio R, Tumolo S and Boiocchi M. Expression of folate binding protein as a prognostic factor for response to platinumcontaining chemotherapy and survival in human ovarian cancer. International journal of cancer Journal international du cancer. 1998; 79:121-126.
9. Iwakiri S, Sonobe M, Nagai S, Hirata T, Wada H and Miyahara R. Expression status of folate receptor alpha is significantly correlated with prognosis in non-small-cell lung cancers. Annals of surgical oncology. 2008; 15:889-899.
10. O'Shannessy DJ, Yu G, Smale R, Fu YS, Singhal S, Thiel RP, Somers EB and Vachani A. Folate receptor alpha expression in lung cancer: diagnostic and prognostic significance. Oncotarget. 2012; 3:414-425.
11. Hartmann LC, Keeney GL, Lingle WL, Christianson TJ, Varghese B, Hillman D, Oberg AL and Low PS. Folate receptor overexpression is associated with poor outcome in breast cancer. International journal of cancer Journal international du cancer. 2007; 121:938-942.
12. O'Shannessy DJ, Somers EB, Maltzman J, Smale R and Fu YS. Folate receptor alpha (FRA) expression in breast cancer: identification of a new molecular subtype and association with triple negative disease. SpringerPlus. 2012; 1:22.
13. Zhang Z, Wang J, Tacha DE, Li P, Bremer RE, Chen H, Wei B, Xiao X, Da J, Skinner K, Hicks DG, Bu H and Tang P. Folate receptor alpha associated with triple-negative breast cancer and poor prognosis. Archives of pathology & laboratory medicine. 2014; 138:890-895.
14. Hoang LL, Qi W, Yu C and Tacha D. SOX10 and folate receptor alpha are frequently expressed in triple negative and progesterone receptor negative breast cancers. Cancer research. 2015; 75:P6-01-13.
15. Chen J, Li S, Shen Q, He H and Zhang Y. Enhanced cellular uptake of folic acid-conjugated PLGA-PEG nanoparticles loaded with vincristine sulfate in human breast cancer. Drug development and industrial pharmacy. 2011; 37:1339-1346.
16. Sun Y, Chen L, Yu J, Zhi X, Tang S, Zhou P and Wang C. Folate-bearing doxorubicin-loaded magnetic poly(Nisopropylacrylamide) microspheres as a new strategy for cancer therapy. Anti-cancer drugs. 2009; 20:607-615.
17. Wang F, Chen Y, Zhang D, Zhang Q, Zheng D, Hao L, Liu Y, Duan C, Jia L and Liu G. Folate-mediated targeted and intracellular delivery of paclitaxel using a novel deoxycholic acid-O-carboxymethylated chitosan-folic acid micelles. International journal of nanomedicine. 2012; 7:325-337.
18. Dosio F, Milla P and Cattel L. EC-145, a folate-targeted Vinca alkaloid conjugate for the potential treatment of folate receptor-expressing cancers. Curr Opin Investig Drugs. 2010; 11:1424-1433.
19. Pribble P and Edelman MJ. EC145: a novel targeted agent for adenocarcinoma of the lung. Expert opinion on investigational drugs. 2012; 21:755-761.
20. Leamon CP, Reddy JA, Vetzel M, Dorton R, Westrick E, Parker N, Wang Y and Vlahov I. Folate targeting enables durable and specific antitumor responses from a therapeutically null tubulysin B analogue. Cancer research. 2008; 68:9839-9844.
21. Naumann RW, Coleman RL, Burger RA, Sausville EA, Kutarska E, Ghamande SA, Gabrail NY, Depasquale SE, Nowara E, Gilbert L, Gersh RH, Teneriello MG, Harb WA, Konstantinopoulos PA, Penson RT, Symanowski JT, et al. PRECEDENT: a randomized phase II trial comparing vintafolide (EC145) and pegylated liposomal doxorubicin (PLD) in combination versus PLD alone in patients with platinum-resistant ovarian cancer. J Clin Oncol. 2013; 31:4400-4406.
22. Leone JP, Lee AV and Brufsky AM. Prognostic factors and survival of patients with brain metastasis from breast cancer who underwent craniotomy. Cancer medicine. 2015.
23. Vranic S, Schmitt F, Sapino A, Costa JL, Reddy S, Castro M and Gatalica Z. Apocrine carcinoma of the breast: a comprehensive review. Histology and histopathology. 2013; 28:1393-1409.
24. Bhargava R, Beriwal S, Striebel JM and Dabbs DJ. Breast cancer molecular class ERBB2: preponderance of tumors with apocrine differentiation and expression of basal phenotype markers CK5, CK5/6, and EGFR. Applied immunohistochemistry & molecular morphology: AIMM /official publication of the Society for Applied Immunohistochemistry. 2010; 18:113-118.
25. Niemeier LA, Dabbs DJ, Beriwal S, Striebel JM and Bhargava R. Androgen receptor in breast cancer: expression in estrogen receptor-positive tumors and in estrogen receptor-negative tumors with apocrine differentiation. Modern pathology: an official journal of the United States and Canadian Academy of Pathology, Inc. 2010; 23:205-212.
26. Dellapasqua S, Maisonneuve P, Viale G, Pruneri G, Mazzarol G, Ghisini R, Mazza M, Iorfida M, Rotmensz N, Veronesi P, Luini A, Goldhirsch A and Colleoni M. Immunohistochemically defined subtypes and outcome of apocrine breast cancer. Clinical breast cancer. 2013; 13:95-102.